Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
PLYMOUTH, Minn., April 20, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 42nd Annual Health Care Conference hosted by Deutsche Bank in Boston, MA.
Entellus Medical’s management is scheduled to present on Thursday, May 4, 2017 at 11:20am ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
